SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients...
• PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.3922 | -47.0151042915 | 0.8342 | 0.85 | 0.4111 | 306789 | 0.49877639 | CS |
4 | -0.313 | -41.4569536424 | 0.755 | 1.04 | 0.4111 | 342294 | 0.82515022 | CS |
12 | -0.4423 | -50.0169625693 | 0.8843 | 1.04 | 0.4111 | 158610 | 0.83031139 | CS |
26 | -0.568 | -56.2376237624 | 1.01 | 1.18 | 0.4111 | 258444 | 0.89915953 | CS |
52 | -0.568 | -56.2376237624 | 1.01 | 1.18 | 0.4111 | 258444 | 0.89915953 | CS |
156 | -0.568 | -56.2376237624 | 1.01 | 1.18 | 0.4111 | 258444 | 0.89915953 | CS |
260 | -0.568 | -56.2376237624 | 1.01 | 1.18 | 0.4111 | 258444 | 0.89915953 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.